High-cost drugs during a Part A SNF stay are the facility's cost unless they fall on CMS's consolidated billing exclusion list, so the planning has to happen before admission. The practical steps are to check the exclusion list, price the drug with your pharmacy, make sure the resident's conditions are fully captured for the PDPM rate, and raise therapeutic alternatives with the prescriber. Asking the family to supply the drug is not a plan; CMS has said the provider agreement precludes it.
What makes a drug "high cost" in a Part A stay?
There is no regulatory definition. For planning, a high-cost drug is one whose daily cost is large relative to the drug portion of your Part A rate. A practical trigger is any drug that costs more per day than the NTA component pays for that resident. The NTA component is the part of the PDPM daily rate that funds non-therapy ancillaries, chiefly drugs. We explain it in PDPM's NTA component and drug costs.
Common examples are oral oncology drugs, some HIV regimens, specialty biologics, and certain antifungals and antivirals. Whether a given drug is costly for you depends on your pharmacy contract.
Who pays for high-cost drugs during a Part A stay?
The facility, in most cases. Under 42 CFR 409.25, drugs the facility ordinarily furnishes to inpatients are part of SNF care, and Part D does not cover a drug when Part A payment is available (42 CFR 423.100).
The exceptions are narrow. The statute excludes certain high-cost, low-probability services from consolidated billing, including specified chemotherapy items identified by HCPCS code. In the FY 2027 SNF PPS final rule, commenters asked CMS to exclude all chemotherapy drugs above a cost threshold. CMS responded that the statute authorizes code-level designations rather than a broad cost-based exemption, and that it evaluates drugs case by case. It said it would review two multiple myeloma drugs commenters had requested.
CMS made a similar point years earlier. In the FY 2019 final rule, it noted that a broader exclusion for expensive non-chemotherapy drugs had been addressed in 2016, when it explained that existing law does not provide for such an expansion.
So the planning starts from the assumption that the drug is yours, and then checks whether it is not. Our guide to SNF consolidated billing exclusions covers the exclusion categories in detail.
What could your building recover?
Two numbers, instant estimate. No email needed.
Why can't the family just supply it?
Because the payment rules put the cost on the facility. In the FY 2018 SNF PPS final rule, CMS answered a question about residents being asked to supply their own high-cost drugs. It said medications needed during a covered stay, with limited exceptions such as certain chemotherapy drugs, are in the per diem, which the SNF must accept as payment in full under its provider agreement.
The OIG's audit A-09-21-03008 found specialty drugs used during Part A stays were mostly supplied by residents or families. Its full report describes a facility that accepted a referral only after the family agreed to supply a lung cancer drug; Part D paid $15,494 for one fill. The facility said the drug cost more than Medicare paid for the entire stay. The OIG is now reviewing why facilities obtained drugs from residents or families. Read more in family-supplied medications during a Part A stay.
Which levers does a facility actually have?
| Lever | What it does | Who decides | Limits |
|---|---|---|---|
| Exclusion check | Moves listed drugs outside your rate | CMS lists; your billing team applies them | Code-specific; check the current year's file and the drug's use |
| Payer check | Medicare Advantage contracts may carve out the drug | The contract | Terms vary by plan; authorization often required |
| Accurate NTA capture | Makes sure documented conditions and services count toward the NTA score | MDS coordinator and clinicians | Only conditions that are present and documented |
| Pharmacy pricing | Lowers the per-dose cost | Your pharmacy services agreement | Depends on contract terms and benchmark |
| Therapeutic alternatives | A lower-cost drug with the same intended effect | Prescriber, with consultant pharmacist input | Clinical decision, not a finance decision |
| Stay planning | Coordinates timing with the hospital or oncologist | Clinical team and the resident | Must follow the resident's care needs |
Three notes on this table. First, for a drug on the exclusion list, the furnishing supplier bills Medicare, typically under Part B, and the line should not be on your invoice. Second, for a Medicare Advantage resident, see Medicare Advantage drug carve-outs. Third, therapeutic choices belong to the prescriber and consultant pharmacist; finance supplies the cost information and nothing more.
How should you run a pre-admission drug review?
- Get the complete medication list. Include specialty, mail-order and infused drugs, not just the hospital discharge summary.
- Flag drugs above your daily trigger. Use a dollar threshold you set, for example the expected NTA payment for a typical resident.
- Check each flagged drug against the current exclusion file. By HCPCS code, and confirm the use, since chemotherapy exclusions apply only when used to treat cancer. Files are on the CMS consolidated billing page.
- Confirm the payer and contract. Original Medicare, or a Medicare Advantage plan with or without a carve-out.
- Get a written price from your pharmacy. Daily cost, any delivery or compounding fees, and whether a lower-cost equivalent is available.
- Estimate expected payment. Likely NTA group, the 3.0 factor for days 1 to 3, and expected length of stay.
- Ask the prescriber and consultant pharmacist about alternatives. If any are clinically appropriate, document the decision.
- Record the admission decision. Who reviewed it, the numbers, and the plan for supply. Admission decisions carry their own regulatory considerations; involve your administrator and, where needed, counsel.
- After admission, supply the drug through your pharmacy. Notify any outside pharmacy to stop Part D fills for the Part A period.
- Review the actual cost at discharge. Compare it with the estimate to improve the next one.
Free · 48 hours · no integration
Get a free 48-hour pharmacy audit
- Send three files: invoices, census, contract
- See overbilling and Part A exposure, line by line
- BAA signed before any data moves
What does the math look like?
The figures below are an illustrative example, not drawn from any client.
A resident is referred on an oral oncology drug that is not on the exclusion list. The pharmacy quotes $520 per day. Other drugs add $45 per day. The expected stay is 21 days, so drug cost is about $11,865.
Using the FY 2027 urban NTA rate of $101.87 and an illustrative case-mix index of 2.00 (a placeholder, not a published value), NTA payment is $611.22 per day for days 1 to 3 and $203.74 per day after that. Over 21 days that is about $5,501. The gap is roughly $6,364 before any other costs.
Known in advance, that is a decision the administrator can make with eyes open, perhaps with a cheaper equivalent the prescriber is comfortable with. Discovered on the invoice six weeks later, it is just a loss.
Who feels this most?
A short-stay or rehab-heavy facility takes the most hospital referrals with specialty drugs in place. An independent nursing home feels a single expensive admission across the whole month's margin. For the payer rules behind all of this, see who pays for drugs during a Part A stay.
This article is general information, not legal, billing or clinical advice. Drug selection belongs to the prescriber and consultant pharmacist.
Frequently asked questions
Does Medicare pay extra for expensive drugs in a SNF?
Only in limited ways. Drugs on the consolidated billing exclusion lists, such as specified chemotherapy codes, are billed separately. Otherwise, the PDPM NTA component pays more for residents with qualifying conditions and services, but it does not pay per drug.
Can CMS add a drug to the consolidated billing exclusion list?
CMS can designate additional items within the statutory categories, such as chemotherapy, by HCPCS code. In the FY 2027 rule it said it reviews requests case by case and declined to exclude drugs by a cost threshold.
Can a SNF refuse an admission because of drug cost?
Admission decisions involve federal and state rules, contracts and anti-discrimination requirements, so this is a question for counsel. What the payment rules do say is that if you admit a Part A resident, the drugs you ordinarily furnish are your cost.
How do we find out if a drug is excluded from consolidated billing?
Check the HCPCS code against the current year's CMS consolidated billing files, and confirm the use. Pharmacy invoices list NDCs, so a crosswalk from NDC to HCPCS is usually needed.
Get the 48-hour first look
Send three months of pharmacy invoices, your census and your pharmacy services agreement. Within 48 hours we show you your high-cost Part A drug lines, which ones may be excluded, and what they cost per resident-day. Request the free 48-hour audit or estimate your numbers with the savings calculator.